Virtual Network's Login.
Chairperson: E. Gluckman
SESSION I – STEM CELL BIOLOGY
– State of the art – T. Enver
– Do we need a different niche for fast haematopoietic reconstitution in cord blood transplantation?
G. Koegler
– Emergence of fetal immune-restricted lympho-myeloid progenitors prior to definitive haematopoietic stem cells -S.E. Jacobsen
– Programming haematopoietic stem cells during development -R. Patient
– UM171 expansion of human CB stem cells -G. Sauvageau
– Cord blood stem cells acquire the signature of induced pluripotent stem cells (iPS) when transplanted
F. Frassoni
SESSION II – METHODS Of GRAFT FACILITATION I
– State of the art – E.J. Shpall
– Stem Regimen-1 Expanded umbilical cord blood transplantation – J. Wagner
– Nicord expands haematopoietic stem cells and shortens time to engraftment in patients undergoing
cord blood transplantation for haematological malignancies and sickle cell disease – J. Kurtzberg
– Rescue of the mucocutaneous manifestations in a mouse model of recessive dystrophic epidermolysis bullosa (RDEB) by human cord blood (CB) derived unrestricted somatic stem cells (USSCS) – M. Cairo
– History and future of cord blood transplantation – E. Gluckman
SESSION III – METHODS Of GRAFT FACILITATION II
– Can MSC facilitate engraftment and haematopoietic reconstitution? – F. Dazzi
– Single versus double cord blood transplant in children – J. Wagner
– Single versus double cord blood transplant in adults – A. Ruggeri
SESSION IV – EVOLUTION IN CORD BLOOD BANKING
– Introduction of the Cord Blood Bank Technology Survey (WMDA-NetCord) – E. Baudoux
– Cost efficiency of cord blood banks – S. Querol
– Use of population data to project cord blood registry size – M. Boo
– Contribution of Eurocord registry to the improvement of cord blood banking – I. Ionescu
SESSION V – IMMUNOGENETICS OF DONOR CHOICE
– State of the art – E. Petersdorf
– Selecting cord blood units in 2015 – M. Eapen
– The role of NK cell killer immunoglobulin receptor genomics on the outcome of cord blood transplantation – K. Rezvani
– The complexity of the MHC in HLA matching with the use of next generation sequencing technologies – A. Madrigal
– Analysis of classical HLA haplotypes can predict outcomes of haematopoietic stem cell transplantation – R. Tamouza
– IRES: an immune reconstitution study of umbilical cord blood transplant recipients – J. Girdlestone
– Impact of CTLA4 genotype and other immune response gene polymorphisms on umbilical cord blood transplantation outcomes – R. Cunha
SESSION VI – ETHICAL AND LEGAL ASPECTS
– So called “MSCs”: concepts and misconceptions, use and misuse, science and empirism – P. Bianco
– Cell-based therapies in Europe: legal requirements and ethical issues – A. Altavilla
– Stem cells from therapy to drug – S. Panis
SESSION VII – CURRENT RESULTS OF CORD BLOOD TRANSPLANTATION RESULTS IN CHILDREN
– Transplantation of cord blood cells as a successful treatment in children with haemoglobinopathies – F. Locatelli
– Importance of CD4+ lymphocyte reconstitution following cord blood transplantation – P. Veys
– Towards individualized conditioning regimens to improve the outcomes of cord blood transplantation – J. Boelens
– UCBT for childhood AML : the impact of cytogenetic – G. Michel
RESULTS IN ADULTS:
– Are the criteria of donor choice in adults different from children ? – V. Rocha
– How to improve cord blood transplant results in adults – J. Sanz
SESSION VIII – IMMUNOMODULATION FOR CORD BLOOD TRANSPLANTATION
– Redirecting T cell specificity post transplant – C. June
– Prevention of GVHD by umbilical cord blood derived T- regulatory cells – J. Wagner
– Therapeutic immune regulation with mesenchymal stromal cells – W. Fibbe
– Engineering intrinsic resistance to HIV infection – C. June
SESSION IX – COMPARISON WITH OTHER SOURCES OF STEM CELLS
– T cell-replete, HLA-haploidentical stem cell transplantation – E. Fuchs
– Comparison of cord blood and non T depleted related haplo transplant in adults – A. Ruggeri
– Comparison of cord blood transplant to T depleted haplo transplant in children – F. Locatelli
– Prospective study on allogeneic transplant in acute myeloid leukaemia according to the policy of the Rome Transplant
network for donor selection: HLA identical sibling vs matched unrelated vs haploidentical related donor – W. Arcese
– Is survival better when patients are enrolled on a clinical trial? – M. Eapen
SESSION X – SELECTED ABSTRACTS FOR ORAL PRESENTATIONS
– Assessment of adhesion and homing molecules alteration in ex vivo expansion of umbilical cord blood CD34+ haematopoietic stem cells – M. N. Zarif
– Comparison of HLA-G expression in mesenchymal stromal cells derived from bone marrow, placenta, umbilical cord and amniotic membrane – M. N. Zarif
– Inventory depuration – L. Ponce-Verdugo
– Clinical utility of family-directed cord blood storage – M. Abecasis
– Comparing volume reduction and quality parameters of large volume cord blood units (CBs) – after cryopreservation with HES and non-HES – the Düsseldorf experience
S.Schwandt
– Comparison of the results of haemoglobin pattern screened in different public health services: umbilical cord blood bank of the Hospital de Clínicas de Porto Alegre (BSCUP-HCPA) and newborn screening reference service of Rio Grande Do Sul (SRTN-RS), Brazil – L.M. Röhsig
– Substantially reduced red cell contamination with comparative nucleated cell recovery using sample specific red cell depletion and plasma reduction technique (a retrospective analysis of 9637 umbilical cord blood units at LifeCell International, India) – P. Dhot
– Umbilical cord blood collection: first year operations at the Canadian Blood Services, National Public Cord Blood Bank – H. Elmoazzen
SESSION XI – in association with Monacord and Centre Scientifique de Monaco :
DEVELOPMENT OF STEM CELL TRANSPLANT IN EMERGING COUNTRIES: THE EXAMPLE OF SICKLE CELL ANAEMIA
– Establishing a haematopoietic stem cells transplant program in sub-Saharan Africa – D. Diallo
– Access to safe and effective transfusion clinical program – S. Diop
– Treatment of sickle cell disease in emerging countries – M. de Montalembert
– Indication of bone marrow transplantation in sickle cell disease – F. Bernaudin
– Bone marrow transplant for sickle cell disease in Brazil – B. Simoes
– International survey of haematopoietic stem cell transplant from an HLA identical sibling for sickle cell disease – B. Cappelli
– Establishing a cost-effective national cord blood registry in a resource restricted environment- S. Narayan
– A potential treatment for beta-thalassemia and sickle cell disease via high-efficiency targeted genome editing of hematopoietic stem cells – M.Walters
SESSION XII – NEW INNOVATIVE THERAPY TO TREAT NON-MALIGNANT DISEASES
– Gene therapy for hereditary disorders – J.A Ribeil
– Update on haematopoietic and mesenchymal cell therapy for the treatment of autoimmunes diseases – D. Farge
– Immunopsychiatry: from pathways to innovative therapies – M. Leboyer & R. Tamouza
– Indications and results of the use of stem cells for regenerative medicine – G. Koegler
– The potential of cord blood to treat genetic and acquired brain diseases – J. Kurtzberg
